Busca avançada
Ano de início
Entree

Desenvolvimento de novas drogas que interagem com GPCRs para tratamento de doenças inflamatórias

Processo: 15/13672-2
Linha de fomento:Bolsas no Brasil - Programa Capacitação - Treinamento Técnico
Vigência (Início): 01 de setembro de 2015
Vigência (Término): 31 de março de 2017
Área do conhecimento:Ciências Biológicas - Farmacologia - Farmacologia Bioquímica e Molecular
Convênio/Acordo: CONFAP ; Newton Fund, com FAPESP como instituição parceira no Brasil ; MRC, UKRI
Pesquisador responsável:Fernando de Queiroz Cunha
Beneficiário:Paulo Peitl Junior
Instituição-sede: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto, SP, Brasil
Vinculado ao auxílio:14/50831-9 - Desenvolvimento de novas drogas que interagem com GPCRs para tratamento de doenças inflamatórias, AP.R
Assunto(s):Fármacos   Desenvolvimento de fármacos   Inflamação

Resumo

Inflammatory diseases are a complex and heterogeneous group of diseases that affect more than 10% of the word population. The current options for the treatment of these diseases are still limited and in some cases, inefficient due to limited understanding of the mechanisms underlying these diseases. In this context, the aim of the present is to create an international collaborative consortium between the Center for Research in Inflammatory Diseases (CRID) located at Ribeirão Preto Medical School (FMRP) and School of Pharmacy of Ribeiro Preto (FCFRP), University of São Paulo (USP), and University of Nottingham (UoN). The overarching objective is to build capacities to promote knowledge transfer and offer relevant training for graduate students from the Partner Institutions, in order to establish a framework for an integrative research in drug discovery. In this context, our objectives will be to identify: 1) to establish an intercontinental collaborative consortium between the University of Nottingham and the University of São Paulo for the study of G protein-coupled receptors relevant to inflammatory disease; 2) to conduct an initial pilot study to develop biased agonists for the beta1-adrenoceptor and evaluate their potential as inotropic agents for the treatment of septic shock following acute infection; 3) to establish a knowledge transfer partnership to enhance bidirectional transfer of knowledge and training among scientists, postdoctoral fellows and graduate students from the Universities of Nottingham and São Paulo. (AU)